PT-141 (Bremelanotide) (Bremelanotide (PT-141 / Vyleesi))
A synthetic melanocortin peptide FDA-approved for HSDD in premenopausal women. Works through CNS to enhance sexual desire rather than vascular mechanisms.
How it works
MC4R agonist in hypothalamus activating central sexual arousal pathways. Increases dopaminergic signaling independent of vascular mechanisms.
Key facts
- Molecular weight: 1,025 Da
- Half-life: 2.7 hours
- Bioavailability: High (SubQ)
- Storage: Room temperature (autoinjector). Lyophilized: 2-8°C.
Dosing overview
- Typical dose: 1.75 mg
- Frequency: As needed, ~45 min before activity
- Duration: As needed
- Route: Subcutaneous injection
Protocol notes
- A single 1.75 mg dose taken roughly 45 minutes before intended activity.
- First-timers often trial a half dose (~1 mg) to gauge nausea before using the full amount.
Reported benefits
- Increased sexual desire
- Central arousal mechanism
- Works both sexes (research)
- Non-vascular
- Rapid onset
Possible side effects
- Nausea (40%)
- Flushing
- Headache
- Transient hypertension
- Skin darkening (rare)
Research
- RECONNECT trials: Bremelanotide for HSDD (2019): Significantly increased sexual desire and reduced distress vs placebo, leading to FDA approval.
- MC4R activation in male sexual dysfunction (2021): Produced erections in 80% of men who failed PDE5 inhibitors via central mechanisms.
Compare PT-141 (Bremelanotide)
Research and educational reference only. Not medical advice.